GLP-1 Trends in 2025: Market Growth and New Approvals

Market Growth and the Scale of the GLP-1 Revolution

The GLP-1 medication class has become the fastest-growing segment in pharmaceutical history by several measures. Global revenues for GLP-1-based therapies surpassed $50 billion in 2024, and analysts project the market will exceed $100 billion annually by 2030. This growth is driven by a confluence of factors: proven clinical efficacy that far exceeds older weight-loss medications, expanding FDA-approved indications beyond diabetes and obesity, growing public awareness fueled by media coverage and patient advocacy, and increasing willingness among both patients and providers to treat obesity as a chronic medical condition rather than a lifestyle choice.

Tirzepatide prescriptions increased 8 percent in Q3 2025 alone, and semaglutide continues to rank among the most prescribed branded medications in the United States. An estimated 30 million or more Americans meet the clinical criteria for GLP-1 treatment, yet only a fraction are currently receiving it. This gap between eligible patients and actual prescriptions represents both an enormous unmet medical need and a massive growth opportunity for the pharmaceutical companies developing these drugs. Supply constraints, insurance coverage gaps, and cost barriers remain the primary obstacles to broader adoption. See our 2025 shortage updates for the latest supply information.

The competitive dynamics of the market are also shifting. While Novo Nordisk and Eli Lilly dominate today, more than a dozen pharmaceutical companies have GLP-1-related programs in various stages of development. This competition is expected to drive innovation in drug delivery, efficacy, and eventually pricing, though meaningful price reductions from generic competition remain years away due to patent protections.

New Drug Approvals and Regulatory Milestones

Several significant regulatory developments have shaped the GLP-1 landscape in 2025. Higher-dose oral semaglutide formulations, specifically 25 mg and 50 mg Rybelsus tablets, represent a major step forward for patients who prefer an oral medication over weekly injections. While the original 14 mg Rybelsus produced modest weight loss compared to injectable semaglutide, the higher doses have shown results that approach injectable efficacy in clinical trials. This development could significantly expand the patient population willing to try GLP-1 therapy.

Zepbound, the weight-management brand of tirzepatide, received expanded labeling that reflects new cardiovascular outcome data. The evidence that GLP-1 medications reduce major adverse cardiovascular events, not just weight, has shifted the clinical conversation from cosmetic weight loss toward comprehensive cardiometabolic risk reduction. This expanded indication strengthens the case for insurance coverage and positions these medications as medically necessary rather than elective.

The FDA has also signaled a more streamlined regulatory pathway for obesity medications generally, recognizing the severity of the obesity epidemic and the need for multiple treatment options. This favorable regulatory environment is encouraging investment in new drug development across the pharmaceutical industry and may accelerate the timeline for bringing next-generation therapies to market.

Pipeline Drugs That Could Reshape Treatment

The pipeline represents a fundamental shift in approach. While first-generation GLP-1 medications target a single receptor, the next wave of therapies targets two or three receptors simultaneously, amplifying weight loss and metabolic benefits. Retatrutide's triple-agonist mechanism, for example, adds glucagon receptor activation to the GIP/GLP-1 approach used by tirzepatide. Glucagon increases energy expenditure and promotes fat breakdown, which helps explain the substantially greater weight loss seen in trials.

The development of oral non-peptide GLP-1 agonists like orforglipron could also transform the market. Current oral semaglutide must be taken on an empty stomach with minimal water, a regimen that many patients find inconvenient. A pill that can be taken without food restrictions would lower the barrier to treatment initiation and potentially improve long-term adherence. Compare current options in our tirzepatide vs semaglutide guide.

Expanded Medical Indications Beyond Obesity

One of the most significant trends in 2025 is the expanding evidence base for GLP-1 medications in conditions beyond obesity and diabetes. The SELECT trial established a 20 percent reduction in major adverse cardiovascular events with semaglutide, a finding that has reshaped how cardiologists view these medications. Ongoing trials are now investigating GLP-1 effects on heart failure with preserved ejection fraction, a condition that disproportionately affects older adults with obesity and has historically had few effective treatments.

Chronic kidney disease is another area where GLP-1 medications are showing protective effects. The FLOW trial demonstrated that semaglutide reduced the risk of kidney disease progression in patients with type 2 diabetes, leading to expanded labeling and potential use in broader populations. Given the strong association between obesity, diabetes, and kidney disease, these findings position GLP-1 medications as potentially disease-modifying across the entire cardiorenal metabolic spectrum.

Metabolic liver disease, formerly known as NASH and now called MASH, represents perhaps the largest potential new market. An estimated 16 million Americans have progressive liver disease related to obesity and metabolic syndrome, and there are very few FDA-approved treatments. Several GLP-1-based medications, including semaglutide and survodutide, have shown dramatic reductions in liver fat and improvement in fibrosis markers. Sleep apnea, Alzheimer's disease, and addiction disorders are also being explored as potential indications. Learn about cardiovascular benefits and GLP-1 effects on addiction.

Access, Affordability, and Insurance Landscape

Access to GLP-1 medications remains one of the most contentious issues in healthcare. At retail prices exceeding $1,000 per month, these medications are unaffordable for most patients without insurance coverage. Yet insurance coverage for weight-loss indications remains inconsistent. The majority of commercial insurance plans now cover Mounjaro and Ozempic for type 2 diabetes, but coverage for Wegovy and Zepbound for weight management without diabetes is far less common.

Several positive developments are improving the picture. More employers are adding anti-obesity medication coverage to their health plans, driven by data showing that these medications reduce downstream healthcare costs from cardiovascular disease, diabetes, and joint problems. The Treat and Reduce Obesity Act, which would require Medicare to cover FDA-approved anti-obesity medications, continues to gain bipartisan support in Congress, though passage remains uncertain. Some states are also considering legislation to mandate coverage.

Compounded versions of semaglutide and tirzepatide have emerged as a significant access pathway for patients who cannot afford brand-name medications or who lack insurance coverage. Compounded formulations are available from FDA-registered pharmacies at substantially lower prices, typically $199 to $400 per month. However, the regulatory landscape for compounding is evolving, and patients should ensure they use reputable pharmacies. Telehealth platforms have also expanded access by making prescriptions available to patients in underserved areas. See cost comparison guide and tirzepatide insurance coverage.

Manufacturing and Supply Chain Developments

Drug shortages have been a persistent challenge since GLP-1 medications gained widespread attention. Both Novo Nordisk and Eli Lilly have announced multibillion-dollar investments in manufacturing expansion to address the demand gap. Novo Nordisk is building new production facilities in Denmark, France, and North Carolina, while Eli Lilly has committed over $9 billion to expanding its manufacturing footprint in the United States and internationally.

These investments are expected to begin alleviating supply constraints throughout 2025 and into 2026, though full supply normalization may take longer given the scale of demand. The complexity of manufacturing injectable biologics, which requires specialized facilities and rigorous quality control, means that ramping up production cannot happen overnight. In the meantime, some dose strengths and formulations continue to experience periodic shortages, and patients are advised to work closely with their pharmacies and providers to manage supply disruptions.

Innovation in drug delivery is also advancing rapidly. Auto-injector devices that simplify self-administration, prefilled pens with longer shelf stability, and implantable formulations that could deliver medication over months rather than weeks are all in various stages of development. These advances could improve adherence and patient experience while potentially reducing manufacturing bottlenecks by requiring less frequent dosing.

What Comes Next: Predictions for 2025 and Beyond

The GLP-1 medication class is still in its relative infancy despite already transforming the treatment landscape for obesity and diabetes. The next five years are likely to bring more effective drugs with fewer side effects, oral formulations that rival injectable efficacy, expanded indications that position these medications as cornerstones of cardiometabolic medicine, and gradually improving affordability as competition increases and patents expire. For patients currently considering or taking GLP-1 medications, the trajectory is overwhelmingly positive, with more options, better access, and stronger evidence emerging on a continuous basis.

Sources

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). NEJM. 2023.
• Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease (FLOW). NEJM. 2024.
• Aronne LJ, et al. Retatrutide Phase 2 Obesity Trial Results. NEJM. 2023.
• FDA Prescribing Information: Wegovy, Ozempic, Mounjaro, Zepbound. 2024-2025.